Department of Neonatology, Pramukhswami Medical College, Shree Krishna Hospital, Bhaikaka University, Karamsad, Gujarat, 388325, India.
Department of Pediatrics, Pramukhswami Medical College, Shree Krishna Hospital, Bhaikaka University, Karamsad, Gujarat, India.
Indian J Pediatr. 2022 Nov;89(11):1086-1092. doi: 10.1007/s12098-022-04166-4. Epub 2022 Jun 1.
To compare the clinical efficacy and the cost of treatment between the newborns who received either a natural or a protein-free synthetic surfactant for respiratory distress syndrome (RDS) of prematurity.
This is a retrospective analytical study incorporating comparisons of clinical parameters and cost in newborns having RDS of prematurity who received either Survanta (bovine lung extract), a natural surfactant or Surfact (protein-free colfosceril palmitate), a synthetic surfactant.
There were 100 newborns who received either of the natural (n = 52) or synthetic (n = 48) surfactant with mean (SD) gestational age and mean (SD) birth weight of 31.5 (2.6) wk, 1425 (461) g and 32.2 (2.2) wk, 1519 (413) g, respectively. Majority of the newborns (> 90%) received endotracheal surfactant within the first 24 h of life and had similar baseline characteristics in either group. No differences were noted in ventilator settings on admission and 24 h after surfactant/admission. Oxygen requirement, extubation age, complications, hospital stay, and mortality were similar across groups, except that the necrotizing enterocolitis was noted only in natural surfactant group. There was a significant pharmacy cost savings in synthetic surfactant group.
Synthetic surfactant was comparable to natural surfactant with regard to outcomes, like ventilator settings, hospital stay, and mortality. Pharmacy cost was less in synthetic surfactant group.
比较接受天然或无蛋白合成表面活性剂治疗的早产儿呼吸窘迫综合征（RDS）新生儿的临床疗效和治疗成本。
这是一项回顾性分析研究，比较了接受天然 Surfactant（牛肺提取物）或合成 Surfact（无蛋白棕榈酸酯）治疗的早产儿 RDS 新生儿的临床参数和成本。
共有 100 名新生儿接受了天然（n=52）或合成（n=48）表面活性剂治疗，平均（SD）胎龄和平均（SD）出生体重分别为 31.5（2.6）周，1425（461）g 和 32.2（2.2）周，1519（413）g。大多数新生儿（>90%）在生命的头 24 小时内接受了气管内表面活性剂治疗，两组的基线特征相似。两组在接受表面活性剂/入院时的呼吸机设置上没有差异。氧需求、拔管年龄、并发症、住院时间和死亡率在各组之间相似，但仅在天然表面活性剂组中观察到坏死性小肠结肠炎。合成表面活性剂组的药房成本有显著节省。
在呼吸机设置、住院时间和死亡率等方面，合成表面活性剂与天然表面活性剂相当。合成表面活性剂组的药房成本较低。
